ISNI

OCLC Meridian makes it possible for libraries to create linked data that connect resources to the wider web

Retrieved on: 
Thursday, May 9, 2024
Metadata, Library, OCLC, MusicBrainz, VIAF, ISNI, WorldCat, MARC, Artificial intelligence, Education for librarianship, API, Organization, Knowledge

DUBLIN, Ohio, May 9, 2024 /PRNewswire/ -- Introducing OCLC Meridian, a web application and set of APIs that libraries and other organizations that manage metadata for knowledge collections can use to create, curate, and connect linked data entities. Published in WorldCat Entities, this linked data is then available for use across a wide variety of services, systems, and data sets to connect to other knowledge streams where people search for information.

Key Points: 
  • Meridian enables the creation of linked data entities and descriptive relationships from within libraries' current workflows, forming connections to existing bibliographic records and other datasets in the global information ecosystem.
  • This new service allows libraries and other organizations managing metadata to contribute to a shared linked data infrastructure.
  • "Libraries of all types and sizes can benefit from and contribute to a scalable, sustainable network of authority linked data.
  • Linked data facilitates greater contextualization of information, makes resources more discoverable, provides opportunities to improve workflows, and supports easier integration of library data into other systems and services.

Frontiers Adopts CCC Ringgold Identify Database as its PID Solution

Retrieved on: 
Tuesday, September 12, 2023
Research, Legal, Technology, Publishing, Security, Communications, Professional Services, Software, Data Management, Science, Metadata, Database, Frontiers, ISO, Article processing charge, ISNI, Open access, ID, APC, CCC, Organization, OA, Acquisition, Pids, PID, Scientific community, Knowledge, Ecosystem, Copyright Clearance Center, Cryptocurrency, Management

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced Gold Open Access (OA) publisher Frontiers has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to help power its OA models by normalizing and disambiguating organization data.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced Gold Open Access (OA) publisher Frontiers has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to help power its OA models by normalizing and disambiguating organization data.
  • With over 600,000 Ringgold PIDs and metadata records, the Ringgold Identify Database provides a curated view of organization data to help stakeholders improve data quality, drive strategic decision-making, and support data interoperability across the scholarly communications ecosystem.
  • Used by intermediaries, funders, institutions, and a growing list of leading publishers, the Ringgold Identify Database is the only solution to offer structured organizational hierarchies and consortia connections to help stakeholders quickly understand complex relationships.
  • The Ringgold Identify Database includes rich metadata and additional identifiers, including the ISNI ID, an open ISO standard to support wider interoperability.

Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology

Retrieved on: 
Wednesday, August 23, 2023
Cone Health Women's Hospital, EA, ISNI, Coronavirus Scientific Advisory Board, PET, MS, Congress, MD, Patient, Mass, Mab, Mass General Brigham, DSM-IV codes, Hospital, AD, FDA, International Society, Pharmaceutical industry, Brigham

Dr. Weiner’s live presentation is scheduled for 11:42 a.m.

Key Points: 
  • Dr. Weiner’s live presentation is scheduled for 11:42 a.m.
  • "We are expanding our understanding of foralumab through rigorous research1 and clinical trials designed to study this potential treatment for neuroinflammatory diseases," said Howard L. Weiner, MD, Chairman of Tiziana's Scientific Advisory Board.
  • Dr. Weiner is also co-director of the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital, a founding member of Mass General Brigham healthcare system.
  • Weiner’s presentation on foralumab, or nasal anti-CD3 mAb will also include updates on our Multiple Sclerosis Expanded Access (EA) program”, commented Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana.

Ashvattha Therapeutics Presents Promising Preclinical Data on New Dendranib Nanomedicine Candidate ASH41020 at the 16th International Society of Neuroimmunology Congress (ISNI)

Retrieved on: 
Tuesday, August 22, 2023
Central nervous system, Cell death, Therapy, Macrophage, Survival, ISNI, EAE, Nanomedicine, Cell, Multiple sclerosis, CNS, MS, Microglia, Poster, Phenotype, Environment, CSF1R, International Society, Disease, Pharmaceutical industry, M1

The preclinical data were presented in a poster at the 16th International Society of Neuroimmunology Congress (ISNI) held at the Centre des Congrès Québec in Québec City, Canada, from August 21st – 24th, 2023, and accessible here .

Key Points: 
  • The preclinical data were presented in a poster at the 16th International Society of Neuroimmunology Congress (ISNI) held at the Centre des Congrès Québec in Québec City, Canada, from August 21st – 24th, 2023, and accessible here .
  • “These data build on previous studies that show our precision nanomedicine therapeutics selectively target activated cells in regions of inflammation.”
    MS is a chronic inflammatory demyelinating disorder of the central nervous system (CNS).
  • In the EAE model of MS, treatment with ASH41020 after disease onset decreased symptom severity in a dose dependent manner.
  • Collectively, these preclinical data show the anti-inflammatory and immunomodulatory potential of ASH41020.

Ashvattha Therapeutics Announces Poster Presentation of Preclinical Data on New ‘Dendranib’ Nanomedicine Candidate at the 16th International Society of Neuroimmunology Congress (ISNI)

Retrieved on: 
Tuesday, August 15, 2023
Therapy, Nanomedicine, ISNI, Phenotype, Multiple sclerosis, Model, International Society, Pharmaceutical industry, Data

Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis

Key Points: 
  • Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis
    REDWOOD CITY, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicine therapeutics, today announced a poster presentation of preclinical data on ASH41020, its new ‘dendranib’ nanomedicine candidate, at the International Society of Neuroimmunology Congress (ISNI) being held August 21 – 24, 2023 in Québec City, Canada.
  • The details of the poster presentation are as follows:
    Poster Title: ASH41020, A Novel Hydroxyl Dendrimer CSF1R Tyrosine Kinase Inhibitor ‘Dendranib’ Nanomedicine, Polarizes Macrophages Toward an Anti-Inflammatory Phenotype and Improves Disease Severity in a Mouse Model of Multiple Sclerosis

Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress

Retrieved on: 
Tuesday, August 8, 2023
Biotechnology, Health, Stem Cells, Pharmaceutical, Oncology, Communication, Northwest Biotherapeutics, CDI, Epstein–Barr virus, GFAP, Lymphoid leukemia, CMC, New Drug Application, NHL, Cancer, ISNI, Biomarker, Sale, MS, EDSS, Chemistry, Plasma, CAR, HIV disease progression rates, Patient, Investment, Glial fibrillary acidic protein, ATRA, Depreciation, Congress, Research, FDA, BLA, IND, International Society, EBV, Vaccine, Pharmaceutical industry, Video game

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upcoming catalysts.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2023, recent business highlights and key upcoming catalysts.
  • “We are pleased to announce IND clearance for ATA3219, our first allogeneic CAR-T cell product candidate expected to enter the clinic in the coming months as a potential best-in-class treatment for patients with certain B-cell malignancies,” said Pascal Touchon, President and Chief Executive Officer of Atara.
  • Second quarter 2022 net income included $50.9 million of deferred revenue recognized due to the termination of the Bayer Collaboration Agreements and a gain on the sale of the ATOM facility of $50.2 million.
  • Total costs and operating expenses include non-cash stock-based compensation, depreciation and amortization expenses of $13.8 million for the second quarter 2023, as compared to $15.6 million for the same period in 2022
    Research and development expenses were $56.1 million for the second quarter 2023, as compared to $64.9 million for the same period in 2022
    General and administrative expenses were $13.3 million for the second quarter 2023, as compared to $18.8 million for the same period in 2022
    General and administrative expenses include $5.4 million of non-cash stock-based compensation expenses for the second quarter 2023, as compared to $6.2 million for the same period in 2022

EQS-News: Immunic to Participate in Investor and Scientific Conferences in August

Retrieved on: 
Tuesday, August 1, 2023
Biotechnology, ISNI, Multiple sclerosis, Patient, NURR1, Congress, Pharmacology, International Congress of Americanists, Conference, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, August 1, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:

Key Points: 
  • NEW YORK, August 1, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:
    August 8-9: 2023 Wedbush PacGrow Healthcare Conference.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Vidofludimus Calcium, an Orally Available DHODH Inhibitor in Phase 3 Clinical Trials for Multiple Sclerosis, Potently Activates NURR1

Immunic to Participate in Investor and Scientific Conferences in August

Retrieved on: 
Tuesday, August 1, 2023
ISNI, Multiple sclerosis, Patient, NURR1, Congress, Pharmacology, International Congress of Americanists, Conference, Pharmaceutical industry, Short course immune induction therapy

NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:

Key Points: 
  • NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:
    August 8-9: 2023 Wedbush PacGrow Healthcare Conference.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Vidofludimus Calcium, an Orally Available DHODH Inhibitor in Phase 3 Clinical Trials for Multiple Sclerosis, Potently Activates NURR1

CCC to Host Interactive Webcast on ‘The State of Scholarly Metadata in 2023: Industry Insights From Around the Globe’

Retrieved on: 
Thursday, July 13, 2023
Data Management, Technology, Professional Services, Publishing, Communications, Other Science, Other Technology, Research, Software, Legal, Science, Database, Learning, Metadata, Association of Learned and Professional Society Publishers, Society, Society for Scholarly Publishing, University, Health, SSP, Culture, ISO, University of Vienna, International Association, ISNI, ORCID, Doctor of Philosophy, London, Open access, ID, Government, Information, CCC, OA, FAIR, Acquisition, Pids, STM, Scientific community, Knowledge, APC, Ecosystem, Unilog Content Solutions, Open Access Scholarly Publishing Association, Copyright Clearance Center, Town hall, London Book Fair, VIP, Management, OASPA, Ethics, Access, ALPSP

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will present an interactive webcast – The State of Scholarly Metadata in 2023: Industry Insights From Around the Globe – on Thursday, 20 July at 11AM EDT/4 PM BST.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, will present an interactive webcast – The State of Scholarly Metadata in 2023: Industry Insights From Around the Globe – on Thursday, 20 July at 11AM EDT/4 PM BST.
  • A VIP panel of industry experts will discuss the importance of prioritizing metadata management for the open scholarly community and explore pragmatic solutions for future publishing workflows.
  • The session is moderated by Deni Auclair , Media Growth Strategies, and Jamie Carmichael , Senior Director, Information and Content Solutions, CCC.
  • “When it comes to moving successful Open Access initiatives forward, high-quality scholarly metadata is crucial,” said Emily Sheahan, Vice President & Managing Director, CCC.

CCC Hosting Panel at The London Book Fair on Reading the Data Compass: The Guiding Role of Metadata in an Increasingly Complex Scholarly Research Ecosystem

Retrieved on: 
Tuesday, April 18, 2023
Software, Research, Entertainment, Books, Data Management, Technology, Other Communications, Publishing, Science, Communications, Other Technology, Other Science, Taylor & Francis, Database, Learning, Association of Learned and Professional Society Publishers, Metadata, Society, Society for Scholarly Publishing, Health, SSP, ISO, International Association, ISNI, London Book Fair, ORCID, Doctor of Philosophy, ID, Open access, Government, CCC, OA, Acquisition, Data, Hearing, Pids, STM, Scientific community, PLOS, Knowledge, APC, Olympia Theatre (New York City), Ecosystem, Open Access Scholarly Publishing Association, Olympia Theatre, Copyright Clearance Center, Environment, Open research, Content, Book, Management, OASPA, ALPSP

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, is hosting a panel discussion on “Reading the Data Compass: The Guiding Role of Metadata in an Increasingly Complex Scholarly Research Ecosystem” during the Research & Scholarly Publishing Forum at The London Book Fair on 20 April, 11:40 -12:10 in the Olympia Theatre .

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, is hosting a panel discussion on “Reading the Data Compass: The Guiding Role of Metadata in an Increasingly Complex Scholarly Research Ecosystem” during the Research & Scholarly Publishing Forum at The London Book Fair on 20 April, 11:40 -12:10 in the Olympia Theatre .
  • The database also includes rich metadata and additional identifiers, including the ISNI ID, an ISO Standard open ID to support wider interoperability.
  • CCC is a long-time supporter of the creation, development, and proliferation of identifiers, including supporting initiatives such as ORCID and ISNI .
  • CCC is a member of OASPA (Open Access Scholarly Publishers Association), ALPSP (Association of Learned and Professional Society Publishers), STM (International Association of STM Publishers) and SSP (Society for Scholarly Publishing).